The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Two-year outcomes of RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Lisa A. Kachnic
Disclosure not yet available
Kathryn A. Winter
Disclosure not yet available
Robert J. Myerson
Disclosure not yet available
Michael D. E. Goodyear
Disclosure not yet available
John Willins
Disclosure not yet available
Jacqueline Esthappan
Disclosure not yet available
Michael G. Haddock
Disclosure not yet available
Marvin Rotman
Disclosure not yet available
Parag J. Parikh
Disclosure not yet available
Christopher G. Willett
Disclosure not yet available